Andrea Sutherland

Learn More
The public health community faces increasing demands for improving vaccine safety while simultaneously increasing the number of vaccines available to prevent infectious diseases. The passage of the US Food and Drug Administration (FDA) Amendment Act of 2007 formalized the concept of life-cycle management of the risks and benefits of vaccines, from early(More)
Vaccines are profoundly important to global health in preventing infectious diseases. Reported adverse events following vaccination are diverse, rare and require thorough investigation and evaluation [1]. Autoimmune diseases (AD) have been reported after some vaccinations. Because autoimmune diseases are rare and have variable and prolonged onset times, it(More)
Advances in genomics are contributing to the development of more effective, personalized approaches to the prevention and treatment of infectious diseases. Genetic sequencing technologies are furthering our understanding of how human and pathogen genomic factors - and their interactions - contribute to individual differences in immunologic responses to(More)
The medical review of adverse event reports for medical products requires the processing of "big data" stored in spontaneous reporting systems, such as the US Vaccine Adverse Event Reporting System (VAERS). VAERS data are not well suited to traditional statistical analyses so we developed the FDA Adverse Event Network Analyzer (AENA) and three novel network(More)
  • 1